Atrial natriuretic peptide
Also known as: ANF, ANP, Atrial natriuretic factor, Atriopeptin, Carperitide, hANP
Source Atrial natriuretic peptide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Atrial natriuretic peptide (ANP) is a cardiac hormone belonging to the natriuretic peptide family. It is investigated primarily for its ability to protect kidney function during acute illness and to influence metabolic pathways such as lipolysis. Research has focused on low‑dose intravenous or subcutaneous administration to prevent or treat acute kidney injury (AKI) and to explore effects on blood pressure and adipokine regulation.
Mechanism of Action
ANP binds to natriuretic peptide receptor‑A on vascular smooth muscle, renal tubular, and adipose cells, activating guanylyl cyclase and raising intracellular cyclic GMP. The rise in cGMP promotes vasodilation, natriuresis, inhibition of renin‑angiotensin‑aldosterone activity, and enhances lipolysis. In humans, NEP inhibition that raises ANP levels has been shown to increase plasma cGMP, supporting this signaling cascade.
What the Research Shows
Systematic reviews of randomized trials (18 RCTs in 2019; 19 RCTs in 2009) suggest low‑dose ANP may halve the incidence of new AKI and markedly reduce the need for renal replacement therapy, especially in patients undergoing major surgery. However, the trials were often small, of low to moderate quality, and trial sequential analyses indicated insufficient sample size to confirm efficacy. A 2023 controlled infusion study in healthy men demonstrated that ANP acutely lowers plasma leptin and raises free fatty acids, indicating metabolic activity. Animal studies with NEP inhibition show dose‑dependent ANP elevation and blood‑pressure reduction, but human data on direct ANP administration remain limited.
Reported Benefits
Available evidence points to possible benefits of low‑dose ANP in preventing AKI, decreasing the requirement for dialysis, and shortening intensive‑care stays in surgical patients. Metabolic observations suggest ANP can lower leptin levels and stimulate lipolysis, which may have implications for energy balance. NEP‑inhibitor studies also show that raising ANP can contribute to blood‑pressure lowering in hypertensive models.
Limitations of the Evidence
The current literature is constrained by small, heterogeneous trials with variable dosing regimens. High‑dose ANP has been linked to trends toward higher mortality and more adverse events, while low‑dose benefits remain unproven in large, multicenter studies. Many analyses note insufficient power and methodological limitations, preventing definitive clinical recommendations.
Safety Considerations
Low‑dose ANP has generally been reported as well tolerated, with a low incidence of hypotension. Some trials noted an increased rate of adverse events, including hypotension, at higher infusion rates, and a possible rise in mortality when high doses were used for established AKI. Caution is advised in patients prone to hemodynamic instability, and monitoring for blood‑pressure changes is recommended.
How It Is Administered
ANP is administered intravenously or subcutaneously as a recombinant peptide formulation (e.g., carperitide). Clinical studies have used short‑term infusions over minutes to hours. No oral formulations are currently described for direct ANP use.
Routes of Administration
Goals & Uses
- Diuretic‑resistant edemaNephrologyLow
- Pulmonary hypertension managementCardiovascularLow
- Acute decompensated heart failureCardiovascularModerate
- Blood pressure reductionCardiovascularModerate
- Natriuresis and diuresisFluid/electrolyte ManagementHigh
- Acute decompensated heart failure treatmentCardiovascularModerate
- Renal protection in acute kidney injuryRenalLow
- Hypertensive emergencyCardiologyLow
- RAAS suppressionCardiovascular/EndocrineHigh
Contraindications
- Severe aortic or mitral stenosisCardiovascularModerate
- Constrictive pericarditis / pericardial tamponadeCardiovascularModerate
- Cardiogenic shockCardiovascularHigh
- Aortic stenosis (critical)CardiacModerate
- Hypersensitivity to ANP or carperitideImmunologicalHigh
- HypotensionCardiovascularHigh
- Severe hypotension (SBP <90 mmHg)HemodynamicHigh
Adverse Effects
- Tachycardia (reflex)CardiovascularUncommon
- HeadacheNeurologicCommonPain in the head or upper neck
- Dizziness / lightheadednessNeurologicCommon
- HypotensionCardiovascularCommonLow blood pressure
- Renal dysfunctionRenalRare
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- Renal dysfunction (↑creatinine)RenalRare
Drug Interactions
- Sodium‑glucose cotransporter‑2 (SGLT2) inhibitorsLow
- Phosphodiesterase inhibitors (e.g., sildenafil)High
- Antihypertensive agentsModerate
- ACE inhibitors / ARBsModerate
- NSAIDsModerateMay increase renal risk in susceptible patients
- ACE inhibitorsModerate
- DiureticsModerateMay worsen dehydration or electrolyte imbalance
Population Constraints
- PregnancyReproductive SafetyRelative
- Hepatic impairmentOrgan FunctionRelative
- Severe renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Pediatric (<1 yr)AgeRelative
- Elderly patientsAgeRelative
Regulatory Status
- European UnionUnapprovedANP not marketed; investigational use only.
- United StatesUnapprovedNo FDA‑approved ANP product; recombinant B‑type peptide (nesiritide) is approved.
- United KingdomUnapprovedNot approved by MHRA as a therapeutic; research use only.
Carperitide (synthetic human ANP) is approved in Japan for acute heart failure. In the US and EU, native ANP is not approved as a therapeutic agent; it is primarily used in research settings. Nesiritide (BNP) is the approved natriuretic peptide therapy in the US for acute decompensated heart failure.
Evidence & Sources
- Journal ArticleHighYamada H, et al.2019-01-01T00:00:00.000000Z
- Journal ArticleModerateGu J, et al.2010-01-01T00:00:00.000000Z
- Journal ArticleModerateDaniels MA, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateWambach G1988-01-01T00:00:00.000000Z
- Journal ArticleHighNigwekar SU, et al.2009-01-01T00:00:00.000000Z
- Journal ArticleModeratePruszczyński W1987-01-01T00:00:00.000000Z
Frequently Asked Questions
What clinical condition is ANP most studied for?
ANP has been most extensively studied as a preventive or therapeutic agent for acute kidney injury, especially in patients undergoing major surgery or in critical‑care settings.
Does ANP affect blood pressure?
Indirectly, yes. By promoting natriuresis and vasodilation through cGMP signaling, ANP can lower blood pressure; this effect has been observed in animal models and when ANP levels rise after neprilysin inhibition.
Are there any metabolic effects of ANP?
A controlled infusion in healthy men showed that ANP acutely reduces leptin concentrations and increases free fatty acids, indicating activation of lipolysis and a role in the heart‑adipose tissue axis.
Is ANP safe to use at high doses?
High‑dose ANP has been associated with trends toward increased mortality and more adverse events in some trials, suggesting that safety is dose‑dependent and that low‑dose regimens are preferred for study.
Is ANP approved for any therapeutic use?
ANP is not approved for routine clinical use; it remains in the research stage, investigated in clinical trials but not licensed for specific indications.
What is Atrial natriuretic peptide?
Atrial natriuretic peptide (ANP) is a cardiac hormone belonging to the natriuretic peptide family. It is investigated primarily for its ability to protect kidney function during acute illness and to influence metabolic pathways such as lipolysis. Research has focused on low‑dose intravenous or subcutaneous administration to prevent or treat acute kidney injury (AKI) and to explore effects on blood pressure and adipokine regulation.
What is Atrial natriuretic peptide used for?
Atrial natriuretic peptide is educationally associated with: Diuretic‑resistant edema, Pulmonary hypertension management, Acute decompensated heart failure, Blood pressure reduction, Natriuresis and diuresis, Acute decompensated heart failure treatment, Renal protection in acute kidney injury, Hypertensive emergency, RAAS suppression. Educational only — not medical advice.
How is Atrial natriuretic peptide administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Atrial natriuretic peptide?
Reported adverse effects include: Tachycardia (reflex), Headache, Dizziness / lightheadedness, Hypotension, Renal dysfunction, Nausea, Renal dysfunction (↑creatinine). This list is not exhaustive — consult a qualified clinician.
Who should avoid Atrial natriuretic peptide?
Recorded contraindications: Severe aortic or mitral stenosis, Constrictive pericarditis / pericardial tamponade, Cardiogenic shock, Aortic stenosis (critical), Hypersensitivity to ANP or carperitide, Hypotension, Severe hypotension (SBP <90 mmHg). Consult a qualified clinician before use.